Advertisement

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba and Michael Hallek

Article Information

PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted June 21, 2017
  • Accepted November 29, 2017
  • Published online December 18, 2017.


Contributors 
  • Natalie Dimier, 1 Roche Products Ltd, Welwyn=, United Kingdom;
  • Paul Delmar, 2 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
  • Carol Ward, 2 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
  • Rodica Morariu-Zamfir, 2 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
  • Günter Fingerle-Rowson, 2 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
  • Jasmin Bahlo, 3 Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Germany;
  • Kirsten Fischer, 3 Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Germany;
  • Barbara Eichhorst, 4 Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hopsital Cologne, Germany;
  • Valentin Goede, 3 Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Germany;
  • Jacques J. M. van Dongen, 5 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Netherlands;
  • Matthias Ritgen, 6 Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany;
  • Sebastian Böttcher, 7 Department of Hematology, Oncology and Palliative Medicine, Center for Internal Medicine, University of Rostock, Germany;
  • Anton W. Langerak, 8 Department of Immunology, Laboratory for Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands;
  • Michael Kneba, 6 Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany;
  • Michael Hallek, 9 Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output